Abstract
Alzheimers disease (AD) is the most prevalent form of dementia, and its effective disease modifying therapies are desperately needed. Promotion of non-amyloidogenic alpha (α)-secretase cleavage of amyloid precursor protein (APP) to release soluble sAPPα, based on the most widely accepted “amyloid model” as a plausible mechanism for AD treatment, is the focus of this review. Modulation of α-secretase or “a disintegrin and metalloprotease (ADAM)”s activity via protein kinase C (PKC), calcium ion (Ca2+), tyrosine kinase (TK), MAP kinase (MAPK), and hormonal signaling, which regulate catabolic processing of APP, are discussed. The inhibition of amyloidogenic processing of APP by the beta (β)-and gamma (γ)-secretase has been considered till now a promising strategy to treat AD. But β- and γ-secretase inhibitors, along with the available therapeutic tools for AD, have side effects. These challenges can be circumvented to certain extent; but activation of sAPPα release appears to be a potential alternative strategy to reduce cerebral amyloidosis. Drug screens have been performed to identify therapeutics for AD, but an effective screening strategy to isolate activators of α-secretase has been rarely reported. Novel reporter-based screens targeted toward APP mRNA 5 untranslated region (UTR), followed by counterscreens to detect α-secretase stimulators, could be important in detecting compounds to promote sAPPα release and reduce amyloid beta (Aβ) buildup. The primary inflammatory cytokine interleukin-1, which stimulates APP 5UTR-directed translation of cell-associated APP, enhances processing to sAPPα in astrocytes and co-activates ADAM-10/ADAM-17 through MAPK signaling; thus illustrating a novel pathway that could serve as therapeutic model for AD.
Keywords: APP proteolysis, soluble sAPPα, ADAM activators, signaling, drug screens, interleukin-1
Current Medicinal Chemistry
Title: Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease
Volume: 14 Issue: 27
Author(s): S. Bandyopadhyay, L. E. Goldstein, D. K. Lahiri and J. T. Rogers
Affiliation:
Keywords: APP proteolysis, soluble sAPPα, ADAM activators, signaling, drug screens, interleukin-1
Abstract: Alzheimers disease (AD) is the most prevalent form of dementia, and its effective disease modifying therapies are desperately needed. Promotion of non-amyloidogenic alpha (α)-secretase cleavage of amyloid precursor protein (APP) to release soluble sAPPα, based on the most widely accepted “amyloid model” as a plausible mechanism for AD treatment, is the focus of this review. Modulation of α-secretase or “a disintegrin and metalloprotease (ADAM)”s activity via protein kinase C (PKC), calcium ion (Ca2+), tyrosine kinase (TK), MAP kinase (MAPK), and hormonal signaling, which regulate catabolic processing of APP, are discussed. The inhibition of amyloidogenic processing of APP by the beta (β)-and gamma (γ)-secretase has been considered till now a promising strategy to treat AD. But β- and γ-secretase inhibitors, along with the available therapeutic tools for AD, have side effects. These challenges can be circumvented to certain extent; but activation of sAPPα release appears to be a potential alternative strategy to reduce cerebral amyloidosis. Drug screens have been performed to identify therapeutics for AD, but an effective screening strategy to isolate activators of α-secretase has been rarely reported. Novel reporter-based screens targeted toward APP mRNA 5 untranslated region (UTR), followed by counterscreens to detect α-secretase stimulators, could be important in detecting compounds to promote sAPPα release and reduce amyloid beta (Aβ) buildup. The primary inflammatory cytokine interleukin-1, which stimulates APP 5UTR-directed translation of cell-associated APP, enhances processing to sAPPα in astrocytes and co-activates ADAM-10/ADAM-17 through MAPK signaling; thus illustrating a novel pathway that could serve as therapeutic model for AD.
Export Options
About this article
Cite this article as:
Bandyopadhyay S., Goldstein E. L., Lahiri K. D. and Rogers T. J., Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease, Current Medicinal Chemistry 2007; 14 (27) . https://dx.doi.org/10.2174/092986707782360060
DOI https://dx.doi.org/10.2174/092986707782360060 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Evaluation of Halogenated Thioureas as Cholinesterases Inhibitors Against Alzheimer’s Disease & Molecular Modeling Studies
Letters in Drug Design & Discovery Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Galanin/GALP Receptors and CNS Homeostatic Processes
CNS & Neurological Disorders - Drug Targets Biomarkers for Alzheimer’s Disease
Current Alzheimer Research Cholesterol and Dementia: A Long and Complicated Relationship
Current Aging Science Antipsychotic Drugs and Cerebrovascular Events in Elderly Patients with Dementia: A Systematic Review
Mini-Reviews in Medicinal Chemistry Social Network Analysis of Dementia Wards in Psychiatric Hospitals to Explore the Advancement of Personhood in Patients with Alzheimer’s Disease
Current Alzheimer Research Statins: Are They All the Same?
Current Drug Therapy Cardiac Amyloid - A Hidden Contributor to Cardiac Dysfunction Following Cardiac Surgery: Case Report and Literature Review
Current Cardiology Reviews Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment
Current Pharmaceutical Design Schizophrenia: Causes and Treatments
Current Pharmaceutical Design Involvement of Advanced Glycation End-products (AGEs) in Alzheimers Disease
Current Alzheimer Research Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimer’s Disease Patients vs. Drug Treated Parkinson’s Disease Patients vs. Age-matched Normal Controls
Current Alzheimer Research A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type
Current Alzheimer Research Inflammation and Arterial Hypertension: From Pathophysiological Links to Risk Prediction
Current Medicinal Chemistry EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Alzheimer's Disease: Emerging Trends in Small Molecule Therapies
Current Medicinal Chemistry Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Extraction, Structure and Bioactivities of the Polysaccharides from Fructus corni
Recent Patents on Food, Nutrition & Agriculture Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Current Alzheimer Research